Trial Profile

A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remtolumab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

12 Sep 2017 Results of pooled analysis of two similarly designed phase 1 studies including this study published in the Arthritis and Rheumatology
25 Jul 2017 Results of pooled analysis from three phase I studies including this study published in the Clinical Pharmacokinetics
13 Jun 2015 Results presented (in pooled analysis of 3 phase I trials) at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com